Hypoxia in Medical Technology

Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)

... transport and thus treating the symptoms of hypoxia at their source. In 2007, the Company ... determine the effect of TSC on potential hypoxia biomarkers; and evaluate the impact of TSC ... to alleviate the claudication pain caused by hypoxia in the tissues of the legs. Additional Clinical ...

Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma

... OS and PFS were 88.9 percent and 69.8 percent, respectively. The primary toxicities observed included grade 3 or 4 mucositis in 21 patients, grade 3 hypoxia in eight patients, and grade 3 pneumonitis, which responded to corticosteroids, in 3 patients. Transplantation-related mortality at 100 days was 0 ...

Threshold Pharmaceuticals Announces Multiple Presentations on Oncology Pipeline at the 2007 American Association for Cancer Research (AACR) Annual Meeting

... 8:00am to 12:00pm: Poster 3988: In Vivo Anti-Cancer Efficacy of a hypoxia Activated Prodrug, TH-302 Poster Session: Angiogenesis Inhibitors Poster 3985: Anti-Tumor Activity of a hypoxia Activated Prodrug, TH-302, in Pancreatic and Prostate Orthotopic ...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

... study, one patient died from eosinophilic pneumonia in the Eloxatin(R) combination arm. The combined incidence of cough, dyspnea, and hypoxia was 43% (7% grade 3 and 4) in the Eloxatin(R) plus 5-FU/LV arm compared to 32% (5% grade 3 and 4) in the irinotecan plus 5-FU/LV arm ...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

... arthralgia, nausea). One patient with multiple prior trastuzumab and doxorubicin containing regimens experienced a dose-limiting toxicity of hypoxia and left ventricular ejection fraction reduction at 100 mg/m2. Two patients treated at 80 mg/m2 experienced reversible Grade 3 ocular keratitis; ...

Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO

... apoptosis (programmed cell death), tumor cell cycle inhibition at the G2/M phase of mitosis, and disruption of angiogenesis through the inhibition of hypoxia inducible factor-1 alpha (HIF-1alpha), a protein required for angiogenesis and cell survival under stress. By these mechanisms, Panzem(R) has ...

Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO

... (PR), and one patient with a 30% reduction in tumor volume. Patients also underwent sequential biopsies of their tumors to evaluate biomarkers of hypoxia and angiogenesis. Paclitaxel causes an increase in tumor HIF-1alpha expression, which is downregulated by 2ME2. Changes were observed in HIF-1 ...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

... EFAPROXYN was generally well tolerated. The most common Grade 3-4 adverse events that occurred more often in the EFAPROXYN arm included headache, hypoxia and vomiting. Adverse events in the study appeared to be similar to those observed in previous clinical studies with EFAPROXYN. "Although we are ...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

... of opioids) were not administered to any subjects in the trial. AeroLEF does not appear to increase the risk of key adverse events (such as hypoxia and bradypnea) and has the potential to minimize certain otherwise expected adverse effects of interest to patients and physicians, warranting ...